hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06367166 id: RyazanSMU briefTitle: Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-01 date: 2026-04-01 date: 2026-05-01 date: 2024-04-16 date: 2024-04-16 name: Ryazan State Medical University class: OTHER briefSummary: The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin). conditions: Varicose Veins of Lower Limb conditions: Varix conditions: Vascular Diseases conditions: Leg Edema studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients with varicose veins will be assigned to different treatments to assess the venous wall remodeling parameters throughout treatment primaryPurpose: BASIC_SCIENCE masking: NONE count: 100 type: ACTUAL name: "Venarus®" (diosmin and hesperidin) name: Endovenous laser ablation (EVLA) with miniphlebectomy name: Elastic compression name: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores measure: changes in biomarkers of venous wall remodeling measure: Changes in biomarkers expression in venous wall sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RyazanSMU city: Ryazan country: Russian Federation lat: 54.6269 lon: 39.6916 hasResults: False
nctId: NCT06367153 id: 1447-0007 id: 2023-510461-10-00 type: REGISTRY domain: CTIS id: U1111-1303-9187 type: REGISTRY domain: WHO International Clinical Trials Registry Platform (ICTRP) briefTitle: A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood overallStatus: NOT_YET_RECRUITING date: 2024-05-07 date: 2024-08-24 date: 2024-08-24 date: 2024-04-16 date: 2024-04-17 name: Boehringer Ingelheim class: INDUSTRY briefSummary: The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates). conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: CROSSOVER interventionModelDescription: Patients cross over from test treatment (T) to reference treatment (R) (two periods, fixed sequence). primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: BI 1569912 name: repaglinide name: midazolam name: bupropion measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) measure: Maximum measured concentration of the analyte in plasma (Cmax) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06367140 id: SYU 2021-06-001-002 briefTitle: Effects of Electromyography-Triggered Constraint-Induced Movement Cycling Therapy on Patients With Chronic Stroke overallStatus: COMPLETED date: 2020-01-01 date: 2022-12-31 date: 2023-12-31 date: 2024-04-16 date: 2024-04-17 name: Sahmyook University class: OTHER name: Seoul National University Hospital name: Kyungdong University briefSummary: The study investigates the potential of Electromyography (EMG)-triggered Constraint-Induced Movement Cycling Therapy (CIMCT) versus General Cycling Training (GCT) to enhance balance, strength, and daily activities in chronic stroke patients. Over a period of four weeks, this single-blind randomized controlled trial aims to explore how these interventions can assist in stroke rehabilitation. The research has been approved by the Ethics Committee of Kyungdong University and adheres to the ethical standards laid out in the Declaration of Helsinki. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The evaluators were blinded to the intervention details of the participants. whoMasked: OUTCOMES_ASSESSOR count: 58 type: ACTUAL name: EMG-triggered CIMCT device name: general cycling training measure: Muscle Strength measure: Static Balance measure: Timed Up and Go (TUG) measure: Berg Balance Scale measure: Functional Reach Test (FRT) measure: Modified Barthel Index (MBI) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Physicla Therapy, Sahmyook University city: Seoul zip: 01795 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06367127 id: Pingfanghu briefTitle: Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening overallStatus: ENROLLING_BY_INVITATION date: 2023-10-09 date: 2024-12-31 date: 2024-12-31 date: 2024-04-16 date: 2024-04-16 name: Shanghai Changzheng Hospital class: OTHER briefSummary: Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or porto-systemic shunt. It manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. According to the symptoms, it is classified as covert HE (CHE) and overt HE (OHE). CHE can progress to OHE and is associated with reduced driving ability, increased risk of accidents and hospitalization and weakened health-related quality of life, resulting in poor prognosis and socio-economic status. However, due to the absence of readily identifiable clinical symptoms and signs, CHE is often neglected in clinical practice.
Presently, the diagnosis of CHE depends on psychometric and neurophysiological tests, including the psychometric hepatic encephalopathy score (PHES), critical flicker frequency (CFF) test, continuous reaction time (CRT) test, inhibitory control test, the SCAN test, and electroencephalography. Among them, PHES is most widely used and recommended by several guidelines. However, it is difficult to screen CHE among all cirrhotic patients in the clinic using PHES because of the time required and a dependence on trained experts.
Moving beans from one container to another with tweezers involves dexterity, agility and coordination.The hypothesis was that the utility of the Clamping Bean Test (CBT) will enable early screening patients with CHE. conditions: Hepatic Encephalopathy conditions: Covert Hepatic Encephalopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Number of Beans Clamping in 1 minute measure: Participants' feedback on CBT1 test sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Changzheng hospital city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06367114 id: ssCART-19-II-1 briefTitle: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-09 date: 2025-12 date: 2024-04-16 date: 2024-04-19 name: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd class: INDUSTRY name: The First Affiliated Hospital of Soochow University name: Peking University People's Hospital briefSummary: This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or Refractory acute lymphoblastic leukemia, including central nervous system infiltration. conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: ssCART-19 name: Fludarabine name: Cyclophosphamide measure: Determine the efficacy of ssCART-19 cells in patients with CD19-positive relapsed or refractory acute B lymphoblastic leukemia (r/r B-ALL). measure: Observe the anti-tumor response of ssCART-19 cells to refractory or relapsed acute lymphoblastic leukemia. measure: Best overall response (BOR)assessment during the 3 months after ssCART-19 infusion. measure: Duration of response (DOR) measure: Recurrence free survival (RFS) measure: Event Free Survival (EFS) measure: Overall survival (OS) measure: Incidence of adverse events following ssCART-19 infusion measure: Pharmacodynamic of ssCART-19 cells measure: Pharmacodynamic of ssCART-19 cells measure: Pharmacodynamic of ssCART-19 cells measure: Anti-drug antibody sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. city: Shanghai state: Shanghai zip: 201210 country: China lat: 31.22222 lon: 121.45806 facility: The First Affiliated Hospital of Soochow University city: Suzhou country: China name: Depei Wu, Dr. role: CONTACT lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06367101 id: 202002525B0 briefTitle: AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson's Disease overallStatus: RECRUITING date: 2022-01-18 date: 2025-05-31 date: 2025-07-31 date: 2024-04-16 date: 2024-04-16 name: Chang Gung University class: OTHER briefSummary: A project aims at addressing gait impairments and non-motor symptoms such as anxiety and stress in Parkinson's disease (PD) patients through a novel approach involving heart rate variability (HRV) feedback and Augmented Reality (AR) training. The project is based on the premise that improving HRV, which reflects the adaptability of the autonomic nervous system, can enhance both motor functions like gait and non-motor symptoms. conditions: Parkinson Disease(PD) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: AR training with gait and HRV feedback measure: Walking Speed measure: Step Length measure: Step Time measure: Time-Domain Index of Heart Rate Variability (HRV)：Standard deviation of RR intervals (SDRR) measure: Time-Domain Index of HRV：pNN50 measure: Time-Domain Index of HRV：Root mean square of successive RR interval differences (RMSSD) measure: Frequency-Domain Index of HRV: Low Frequency (LF) measure: Frequency-Domain Index of HRV: High Frequency (HF) measure: Frequency-Domain Index of HRV: Ratio of LF to HF Power measure: Total Time to Complete the Time Up and Go test (TUG test) measure: Double Support Time measure: Single Support Time measure: Swing Time measure: Stance Time measure: Cadence measure: Total UPDRS-III Score measure: Total NFOG-Q Score measure: Overall PDQ-39 Score measure: Total HADS Score measure: Overall PSQI Score measure: Non-linear Index of HRV: SD1 measure: Non-linear Index of HRV: SD2 measure: Non-linear Index of HRV: Ratio of SD1-to-SD2 sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung University status: RECRUITING city: Taoyuan zip: 333 country: Taiwan name: Ya-Ju Chang, PhD role: CONTACT phone: 88632118800 phoneExt: 5515 email: yjchang@mail.cgu.edu.tw lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06367088 id: Sophia briefTitle: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer overallStatus: RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2027-04-30 date: 2024-04-16 date: 2024-04-16 name: Wuhan Union Hospital, China class: OTHER briefSummary: The prognosis of recurrent and metastatic triple negative breast cancer (TNBC) is poor, and chemotherapy is still the main treatment for TNBC. Some studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxicities. Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting PD-1 and CTLA-4. It mutates to eliminate Fc receptor and complement-mediated cytotoxic effects. The purpose of this study is to evaluate the efficacy and safety of Cadonilimab combined with chemotherapy as a first or second-line treatment of recurrent and metastatic TNBC. This study is a multicenter, single arm, phase II, non randomized, open label, Simon two-stage design. It is planned to enroll 27 late stage TNBC patients. conditions: Triple-negative Breast Cancer conditions: Cadonilimab studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: Cadonilimab measure: Objective Response Rate measure: AE measure: Progression-free survival measure: Overall survival measure: Disease control rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology status: RECRUITING city: Wuhan state: Hubei zip: 430022 country: China name: Jie Xiong role: CONTACT phone: +8615927611872 email: xxiongjie2000@163.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06367075 id: AK104-sarcoma-202401 briefTitle: A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-03-31 date: 2029-03-31 date: 2024-04-16 date: 2024-04-16 name: Wuhan Union Hospital, China class: OTHER name: Sun Yat-sen University name: Xiangya Hospital of Central South University name: Yunnan Cancer Hospital name: The Affiliated Hospital Of Guizhou Medical University name: First Affiliated Hospital of Guangxi Medical University briefSummary: This is a single-arm, multicenter trial of cadonilimab (AK104) with adriamycin in patients with first-line advanced soft tissue sarcoma. the primary objective is to evaluate objective response rate of cadonilimab with adriamycin. conditions: Advanced Soft-tissue Sarcoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: cadonilimab (AK104) with adriamycin primaryPurpose: TREATMENT masking: NONE count: 53 type: ESTIMATED name: Cadonilimab name: Adriamycin measure: objective response rate (ORR) measure: Disease control rate (DCR) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Adverse event (AE) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06367062 id: SH9H-2023-T296 briefTitle: General Anesthesia/Surgical Exposure on White Matter Development in Children overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-11-30 date: 2026-12-31 date: 2024-04-16 date: 2024-04-16 name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University class: OTHER briefSummary: International large-scale clinical studies have found that prolonged or repeated exposure to general anesthesia drugs in infancy and early childhood can lead to an increased risk of long-term neurodevelopmental abnormalities in children. The study of neurodevelopmental toxicity of general anesthesia drugs is of great social significance. We have established a rhesus monkey model to study the neurodevelopmental toxicity of general anesthetic drugs, the first time to make a preliminary exploration of the mechanism of myelin developmental toxicity of general anesthetic drugs. Several studies using magnetic resonance scanning found a positive correlation between the number of anesthesia exposures and the maturity of distant brain white matter development in juvenile non-human primates. Clinical evidence for myelin developmental toxicity induced by general anesthetic drugs needs to be collected by conducting multicenter and large-sample clinical studies. Earlier studies have either had low sample sizes, which do not allow for better control of confounding factors; or the study population has been limited to specific disease populations, and the results cannot be extrapolated to normal children. In view of this, based on the applicant's earlier study, this project proposes to recruit children who underwent general anesthesia surgery between 0-3 years of age and are now 12-15 years old; children who did not experience surgery between 0-3 years of age were matched by age-sex to serve as a control group. MRI will be used to assess their brain white matter development, to explore the correlation between anesthesia and anesthesia-related factors and brain white matter development and related neurobehavioral development, and to clarify the effects of anesthesia and surgery on children's brain white matter and related neuropsychological development. conditions: Neurodevelopmental Delay studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 210 type: ESTIMATED name: MRI measure: MRI-based assessment of brain development sex: ALL minimumAge: 12 Years maximumAge: 15 Years stdAges: CHILD hasResults: False
nctId: NCT06367049 id: 2023-FXY-230-NPC briefTitle: Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma overallStatus: COMPLETED date: 2023-06-01 date: 2023-09-30 date: 2024-03-01 date: 2024-04-16 date: 2024-04-16 name: Sun Yat-sen University class: OTHER name: Guangdong Women and Children Hospital name: Affiliated Cancer Hospital & Institute of Guangzhou Medical University briefSummary: Nasopharyngeal carcinoma is one of the most common malignant tumors in China, with the progress of radiochemical comprehensive treatment, early stage The 5-year survival rate of nasopharyngeal cancer is more than 95%. However, due to the hidden site of nasopharyngeal carcinoma and the lack of obvious early clinical symptoms, more than 70% of the 87,000 newly diagnosed cases each year belong to the advanced stage of nasopharyngeal carcinoma, and the 5-year survival rate of advanced nasopharyngeal carcinoma is only about 70%. Therefore, early screening and diagnosis and early treatment are the key to improve the survival of patients with nasopharyngeal cancer. Selecting a sensitive and accurate biomarker for nasopharyngeal cancer and relying on a simple and feasible examination method for sampling detection will greatly improve the early diagnosis rate of nasopharyngeal cancer.
DNA methylation is a form of chemical modification of DNA that can be done without altering the DNA sequence changes in genetic expression. The main role of DNA methylation is to regulate gene expression. Tumor suppressor genes play the functions of regulating cell differentiation, maturation and programmed death. However, if methylation of promoter region occurs, the expression of tumor suppressor genes is inhibited and the function is lost, resulting in cells remaining in the stage of low differentiation and proliferation, inhibition of apoptosis, formation of blood vessels by cluster cells, loss of cell adhesion, and formation of tumors. It can be seen that DNA methylation occurs in the early stage of tumor, and this biological feature makes it a strong application prospect in early tumor screening.
There are many methods to detect DNA Methylation, among which methylation-specific PCR (MSP) can easily and quickly determine the methylation status of a specific gene, meeting the affordable, convenient, and easy to generalize characteristics required for screening tests. In combination with previous MSP experiments and previous reports, we found that the methylation levels of promoter fragments of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues were significantly higher than those in healthy human nasopharyngeal tissues. This suggests that methylation of these three genes may be used as biomarkers for early screening and diagnosis of nasopharyngeal carcinoma.
Therefore, this study intends to detect the methylation status of H4C6, Septin9 and RASSF1A genes based on MSP method with simple operation and low cost. Using clinicopathological diagnosis as the gold standard, the value of this gene methylation index in early screening and early diagnosis of nasopharyngeal cancer was verified, providing a new detection index and method for improving the early diagnosis rate of nasopharyngeal cancer. conditions: Nasopharyngeal Carcinoma conditions: Early Diagnosis of Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 470 type: ACTUAL name: Methylation-specific PCR measure: Sensitivity measure: Specificity sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun yat-sen University Cancer Center city: Guangzhou state: Guangdong zip: 510060 country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06367036 id: 2021-52 briefTitle: Effect of Hypericum Perforatum Oil on Ecchymosis and Pain overallStatus: COMPLETED date: 2022-01-02 date: 2022-12-29 date: 2023-06-15 date: 2024-04-16 date: 2024-04-16 name: Uskudar University class: OTHER briefSummary: Low molecular weight heparin is a drug with anticoagulant and antithrombotic effects. This drug is frequently administered subcutaneously to patients by nurses. Complications such as pain, ecchymosis and hematoma may commonly occur at the injection site. This study investigated the effect of Hypericum Perforatum oil in preventing pain and ecchymosis after subcutaneous injection low molecular weight heparin. This quasi-experimental and single blinded study was conducted with 160 patients in a coronary intensive care unit. The researcher nurse applied 5-6 drops of Hypericum Perforatum oil to one arm of the patients 2 hours before the injection. The other arm of the patient was considered as the control arm. A total of 320 injections were administered. The evaluation of the injection sites was performed by two other researchers at 48th hours. The data were analyzed using Wilcoxon and McNemar test. conditions: Pain conditions: Ecchymosis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: There is no control group in this research design. The participants themselves are also the control group. Intervention was applied to one injection site of the participants 2 hours before the injection and not to the other. Post-injection pain and ecchymosis were evaluated for both sites. The two researchers who analyzed the results do not know the region where the intervention was applied. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Two researchers do not know which site was injected. whoMasked: INVESTIGATOR count: 160 type: ACTUAL name: Topical hypericum perforatum oil intervention measure: Pain point measure: Ecchymosis sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hatice Demirdağ city: Üsküdar state: İstanbul zip: 34672 country: Turkey lat: 41.02252 lon: 29.02369 hasResults: False